B. Riley raised the firm’s price target on ClearPoint Neuro (CLPT) to $28 from $20 and keeps a Buy rating on the shares following a transfer of coverage. ClearPoint is a medical device company focused on providing image-guided navigation for minimally invasive neuro procedures, the analyst tells investors in a research note. The firm says the company’s core business continues to grow over 20% annually, and that it expects significant growth in the future as biopharma partnerships progress towards regulatory approvals and commercial launches.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLPT:
- ClearPoint Neuro announces market release of Navigation Software Version 3.0
- ClearPoint Neuro price target raised to $25 from $19 at Stifel
- ClearPoint Neuro’s Earnings Call Highlights Robust Growth
- ClearPoint Neuro Achieves Record Growth in 2024
- ClearPoint Neuro reports Q4 revenue $7.8M, consensus $8.23M